MTHFD2 and acute myeloid leukemia: As MTHFD2 has been validated with small hairpin RNA as a target in AML19, we next validated our inhibitors in a panel of leukemia cell lines, including acute lymphoblastic leukemia (ALL) and AML cells, as well as nontumorigenic LCLs established from healthy donors, LCL-534 and LCL-889.